BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33237279)

  • 1. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population.
    Greve AM; Christoffersen M; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    JAMA Cardiol; 2021 Mar; 6(3):258-266. PubMed ID: 33237279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.
    Coniglio AC; Segar MW; Loungani RS; Savla JJ; Grodin JL; Fox ER; Garg S; de Lemos JA; Berry JD; Drazner MH; Shah S; Hall ME; Shah A; Khan SS; Mentz RJ; Pandey A
    JACC Heart Fail; 2022 Feb; 10(2):129-138. PubMed ID: 35115086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.
    Parcha V; Malla G; Irvin MR; Armstrong ND; Judd SE; Lange LA; Maurer MS; Levitan EB; Goyal P; Arora G; Arora P
    JAMA; 2022 Apr; 327(14):1368-1378. PubMed ID: 35377943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
    Kamstrup PR; Tybjaerg-Hansen A; Steffensen R; Nordestgaard BG
    JAMA; 2009 Jun; 301(22):2331-9. PubMed ID: 19509380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
    Sikora JL; Logue MW; Chan GG; Spencer BH; Prokaeva TB; Baldwin CT; Seldin DC; Connors LH
    Hum Genet; 2015 Jan; 134(1):111-21. PubMed ID: 25367359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
    Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
    JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
    Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
    Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.
    Rowczenio D; Quarta CC; Fontana M; Whelan CJ; Martinez-Naharro A; Trojer H; Baginska A; Ferguson SM; Gilbertson J; Rezk T; Sachchithanantham S; Mahmood S; Manwani R; Sharpley F; Wechalekar AD; Hawkins PN; Gillmore JD; Lachmann HJ
    Hum Mutat; 2019 Jan; 40(1):90-96. PubMed ID: 30328212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
    Haring B; Hunt RP; Shadyab AH; Eaton C; Kaplan R; Martin LW; Panjrath G; Kuller LH; Assimes T; Kooperberg C; Wassertheil-Smoller S
    JACC Heart Fail; 2023 Sep; 11(9):1189-1199. PubMed ID: 36930136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Burden of the V142I Transthyretin Variant.
    Selvaraj S; Claggett B; Shah SH; Mentz RJ; Khouri MG; Manichaikul AW; Khan SS; Rich SS; Mosley TH; Levitan EB; Arora P; Goyal P; Haring B; Eaton CB; Cheng RK; Wells GL; Manson JE; Fontana M; Solomon SD
    JAMA; 2024 Jun; 331(21):1824-1833. PubMed ID: 38734952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.
    De Lillo A; De Angelis F; Di Girolamo M; Luigetti M; Frusconi S; Manfellotto D; Fuciarelli M; Polimanti R
    Hum Genet; 2019 Dec; 138(11-12):1331-1340. PubMed ID: 31659433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein M and Risk of Type 2 Diabetes.
    Hajny S; Christoffersen M; Dalila N; Nielsen LB; Tybjærg-Hansen A; Christoffersen C
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32621749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amyloidogenic V122I transthyretin variant in elderly black Americans.
    Quarta CC; Buxbaum JN; Shah AM; Falk RH; Claggett B; Kitzman DW; Mosley TH; Butler KR; Boerwinkle E; Solomon SD
    N Engl J Med; 2015 Jan; 372(1):21-9. PubMed ID: 25551524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy.
    Hornstrup LS; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1441-7. PubMed ID: 23580146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
    Kozlitina J; Garg S; Drazner MH; Matulevicius SA; Ayers C; Overton J; Reid J; Baras A; Rao K; Pandey A; Berry J; de Lemos JA; Grodin JL
    J Card Fail; 2022 Mar; 28(3):403-414. PubMed ID: 34634447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.
    Kamstrup PR; Nordestgaard BG
    JACC Heart Fail; 2016 Jan; 4(1):78-87. PubMed ID: 26656145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US.
    Selvaraj S; Claggett BL; Quarta CC; Yu B; Inciardi RM; Buxbaum JN; Mosley TH; Shah AM; Dorbala S; Falk RH; Solomon SD
    JAMA Cardiol; 2023 Aug; 8(8):784-788. PubMed ID: 37212191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.